Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been assigned a €68.00 ($80.00) price target by investment analysts at The Goldman Sachs Group in a research note issued to investors on Tuesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 16.52% from the company’s previous close.
FME has been the subject of several other reports. Independent Research set a €76.00 ($89.41) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a report on Wednesday, February 3rd. JPMorgan Chase & Co. set a €51.10 ($60.12) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a report on Friday, February 12th. Jefferies Financial Group set a €60.00 ($70.59) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “sell” rating in a research report on Tuesday. UBS Group set a €72.00 ($84.71) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Wednesday, February 17th. Finally, Sanford C. Bernstein set a €61.00 ($71.76) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research note on Tuesday, February 16th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of €70.18 ($82.56).
FME stock opened at €58.36 ($68.66) on Tuesday. The stock’s 50 day simple moving average is €64.87 and its 200 day simple moving average is €69.21. The company has a current ratio of 1.11, a quick ratio of 0.71 and a debt-to-equity ratio of 103.14. Fresenius Medical Care AG & Co. KGaA has a 12-month low of €53.50 ($62.94) and a 12-month high of €79.96 ($94.07). The stock has a market capitalization of $17.09 billion and a PE ratio of 12.99.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Story: Support Level
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.